Advice
Likely place in therapy
Likely place in therapy
As with all biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, Remsima (subcutaneous) would be prescribed and initiated in secondary care. Unlike intravenous infliximab, which is usually administered in secondary care rheumatology clinics, Remsima (subcutaneous) can be self-administered at home if the person, family member or carer has been given the appropriate training.
In practice Remsima (subcutaneous) is most likely to be used in people:
-
who are already established on intravenous infliximab
-
with stable disease but who have difficulty attending hospital appointments
-
in whom the risk of attending hospital for intravenous infusions outweighs the benefits.
It may also be beneficial for people who are starting on infliximab who have not used a biologic before or who are switching from a biologic with a different mechanism of action to the tumour necrosis factor (TNF)‑alpha inhibitors.
There are no data on people switching to Remsima (subcutaneous) from Remsima (intravenous) at doses higher than 3 mg/kg or frequencies of administration higher than every 8 weeks, and there are no data on people switching from other infliximab products to Remsima (subcutaneous).